Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa
about
Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerDynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protectionSemimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Clinical significance of microbial infection and adaptation in cystic fibrosis.Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of CiprofloxacinGlobal fluoroquinolone resistance epidemiology and implictions for clinical use.Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammationResistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaAssociation between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosaNosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.A global view of antibiotic resistance.Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.The problems of antibiotic resistance in cystic fibrosis and solutions.Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain.Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutationEffect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice.Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosaAzithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
P2860
Q26825326-93EBF9D9-FF26-4193-96BC-8B3B18CD8A7FQ31029779-D7BD9ABA-78A8-4C63-90DA-21ACDF855A3BQ33386642-866B8756-C967-4BAA-955A-8AFBD61C1231Q33876563-778810A6-2AEA-40E1-B50D-BA34C57376F1Q34297656-EC4C224C-AFCE-4BEC-9297-AD4C18A9B559Q34491552-A700AB87-C60B-4B91-8CB5-6B90AFFF4DE2Q35065847-B2C91DE5-C833-48ED-A386-757AC3014C66Q35879111-637D2F8D-0FA8-41E4-9810-33B326020673Q35939649-138BD2B6-8871-4873-8863-FD5A4F10E61EQ36095041-7B3EC88A-357E-44A1-A608-D8B5F56D0406Q36228925-476B3169-C47C-493F-A5B0-C3D1B73FCE27Q36337074-B93670E9-8FF8-4E89-AA77-8E4E81AF2125Q36421553-D4805E5B-B0F9-4B3A-A953-CD5B05019147Q36744840-67D7A074-5260-428B-A016-C08E019B1342Q36757725-D83DDC0F-B2FA-4F7E-8AA2-B0A54886DA17Q36887819-3A697F47-CEDF-49F7-9854-CDA197FD721BQ36933558-22949589-0882-406B-9FAC-DBCB7FA5FCDDQ37302114-30CE214A-E3ED-4486-BA2B-54B7EFC5817DQ37340607-9D51DCEE-7E7C-49FE-BE41-07A8AED01C46Q38006032-A045A335-C1E7-47FD-AA4E-989D1A329547Q38268531-47D86A4B-F71A-4528-A8D7-C0FEE1A6790EQ38300820-7D07F722-585B-4D3B-AC2B-8219DB9E08CBQ40056971-2FD58CD7-7E21-44B1-86C5-46BA776BFB38Q41366386-7EE4D974-E726-45A6-AA00-E072C2B27E71Q41833848-24E10B2D-E11D-4F07-8934-7C97FF50D3D2Q42560500-00342590-7DA6-434F-8761-D9E3D759A72CQ42572942-E2825A57-E922-450E-90BC-61176E9B3664Q43153453-17137785-1AA2-4915-96D0-B25B554F96BB
P2860
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@ast
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@en
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@nl
type
label
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@ast
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@en
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@nl
prefLabel
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@ast
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@en
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@nl
P2093
P2860
P1476
Efficacy and potential for res ...... mutable Pseudomonas aeruginosa
@en
P2093
P2860
P304
P356
10.1128/AAC.50.3.975-983.2006
P407
P577
2006-03-01T00:00:00Z